Verve Therapeutics logo

Verve TherapeuticsNASDAQ: VERV

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

17 June 2021

Next earnings report:

27 February 2025

Last dividends:

N/A

Next dividends:

N/A
$391.57 M
-84%vs. 3y high
62%vs. sector
-vs. 3y high
-vs. sector
-90%vs. 3y high
34%vs. sector
-99%vs. 3y high
84%vs. sector

Price

regular market | 1 min ago
$4.63+$0.01(+0.33%)

Dividend

No data over the past 3 years
$6.87 M$4.24 M
$6.87 M-$50.13 M

Analysts recommendations

Institutional Ownership

VERV Latest News

Verve Therapeutics (VERV) Reports Q3 Loss, Tops Revenue Estimates
zacks.com05 November 2024 Sentiment: POSITIVE

Verve Therapeutics (VERV) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.72 per share a year ago.

Lost Money on Verve Therapeutics, Inc. (VERV)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
accesswire.com28 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 28, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/verve-therapeutics-inc-lawsuit-submission-form?prid=109623&wire=1 or contact Joseph E. Levi, Esq.

Verve Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights - VERV
prnewswire.com28 October 2024 Sentiment: NEGATIVE

NEW YORK , Oct. 28, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV). Shareholders who purchased shares of VERV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
accesswire.com28 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 28, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/verve-therapeutics-inc-lawsuit-submission-form?prid=109723&wire=1 or contact Joseph E. Levi, Esq.

VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV
globenewswire.com27 October 2024 Sentiment: NEGATIVE

NEW YORK, Oct. 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Verve Therapeutics, Inc. (NASDAQ: VERV) between August 9, 2022 and April 1, 2024, both dates inclusive (the “Class Period”), of the important October 28, 2024 lead plaintiff deadline in the securities class action first filed by the firm.

DEADLINE APPROACHING: Verve Therapeutics Inc Is Being Sued For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm
accesswire.com27 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 9, 2022, and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.

FINAL REMINDER VERV DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Verve Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit!
accesswire.com27 October 2024 Sentiment: NEGATIVE

NEW YORK CITY, NY / ACCESSWIRE / October 27, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Verve Therapeutics, Inc. ("Verve Therapeutics" or "the Company") (NASDAQ:VERV) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Verve Therapeutics securities between August 9, 2022, and April 1, 2024, inclusive (the "Class Period").

VERV Deadline: Rosen Law Firm Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action Commenced by the Firm – VERV
businesswire.com26 October 2024 Sentiment: NEGATIVE

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Verve Therapeutics, Inc. (NASDAQ: VERV) between August 9, 2022 and April 1, 2024, both dates inclusive (the “Class Period”), of the important October 28, 2024 lead plaintiff deadline in the securities class action first filed by the firm. So what: If you purchased Verve Therapeutics securities during the Class Period you may be entitled to compensation without payment of any ou.

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
prnewswire.com25 October 2024 Sentiment: NEGATIVE

NEW YORK , Oct. 25, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Verve Therapeutics, Inc. (NASDAQ: VERV) between August 9, 2022 and April 1, 2024, both dates inclusive (the "Class Period") of the important October 28, 2024 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased Verve Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc. - VERV
prnewswire.com25 October 2024 Sentiment: NEGATIVE

NEW YORK , Oct. 25, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Verve Therapeutics, Inc. ("Verve" or the "Company") (NASDAQ: VERV).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

What type of business is Verve Therapeutics?

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

What sector is Verve Therapeutics in?

Verve Therapeutics is in the Healthcare sector

What industry is Verve Therapeutics in?

Verve Therapeutics is in the Biotechnology industry

What country is Verve Therapeutics from?

Verve Therapeutics is headquartered in United States

When did Verve Therapeutics go public?

Verve Therapeutics initial public offering (IPO) was on 17 June 2021

What is Verve Therapeutics website?

https://www.vervetx.com

Is Verve Therapeutics in the S&P 500?

No, Verve Therapeutics is not included in the S&P 500 index

Is Verve Therapeutics in the NASDAQ 100?

No, Verve Therapeutics is not included in the NASDAQ 100 index

Is Verve Therapeutics in the Dow Jones?

No, Verve Therapeutics is not included in the Dow Jones index

When was Verve Therapeutics the previous earnings report?

No data

When does Verve Therapeutics earnings report?

The next expected earnings date for Verve Therapeutics is 27 February 2025